|
1
|
MicroRNA-29b induces global DNA hypomethylation and tumor suppressor gene reexpression in acute myeloid leukemia by targeting directly DNMT3A and 3B and indirectly DNMT1.
|
Blood
|
2009
|
5.87
|
|
2
|
Chronic lymphocytic leukemia T cells show impaired immunological synapse formation that can be reversed with an immunomodulating drug.
|
J Clin Invest
|
2008
|
3.89
|
|
3
|
TET2 mutations improve the new European LeukemiaNet risk classification of acute myeloid leukemia: a Cancer and Leukemia Group B study.
|
J Clin Oncol
|
2011
|
3.01
|
|
4
|
Higher doses of lenalidomide are associated with unacceptable toxicity including life-threatening tumor flare in patients with chronic lymphocytic leukemia.
|
J Clin Oncol
|
2008
|
2.79
|
|
5
|
Preclinical activity of a novel CRM1 inhibitor in acute myeloid leukemia.
|
Blood
|
2012
|
2.65
|
|
6
|
Lenalidomide treatment promotes CD154 expression on CLL cells and enhances production of antibodies by normal B cells through a PI3-kinase-dependent pathway.
|
Blood
|
2009
|
2.39
|
|
7
|
Lenalidomide down-regulates the CD20 antigen and antagonizes direct and antibody-dependent cellular cytotoxicity of rituximab on primary chronic lymphocytic leukemia cells.
|
Blood
|
2008
|
2.24
|
|
8
|
Bortezomib induces DNA hypomethylation and silenced gene transcription by interfering with Sp1/NF-kappaB-dependent DNA methyltransferase activity in acute myeloid leukemia.
|
Blood
|
2007
|
2.15
|
|
9
|
Genome-wide methylation profiling in decitabine-treated patients with acute myeloid leukemia.
|
Blood
|
2012
|
1.97
|
|
10
|
PP2A-activating drugs selectively eradicate TKI-resistant chronic myeloid leukemic stem cells.
|
J Clin Invest
|
2013
|
1.72
|
|
11
|
Effects of pretransplantation treatment with rituximab on outcomes of autologous stem-cell transplantation for non-Hodgkin's lymphoma.
|
J Clin Oncol
|
2004
|
1.70
|
|
12
|
Characterization of in vitro and in vivo hypomethylating effects of decitabine in acute myeloid leukemia by a rapid, specific and sensitive LC-MS/MS method.
|
Nucleic Acids Res
|
2007
|
1.62
|
|
13
|
Donor CMV serostatus has no impact on CMV viremia or disease when prophylactic granulocyte transfusions are given following allogeneic peripheral blood stem cell transplantation.
|
Blood
|
2002
|
1.48
|
|
14
|
Lower dose of antithymocyte globulin does not increase graft-versus-host disease in patients undergoing reduced-intensity conditioning allogeneic hematopoietic stem cell transplant.
|
Leuk Lymphoma
|
2014
|
1.42
|
|
15
|
RNA-dependent inhibition of ribonucleotide reductase is a major pathway for 5-azacytidine activity in acute myeloid leukemia.
|
Blood
|
2012
|
1.33
|
|
16
|
Phase I study of oblimersen sodium, an antisense to Bcl-2, in untreated older patients with acute myeloid leukemia: pharmacokinetics, pharmacodynamics, and clinical activity.
|
J Clin Oncol
|
2005
|
1.33
|
|
17
|
Targeted delivery of microRNA-29b by transferrin-conjugated anionic lipopolyplex nanoparticles: a novel therapeutic strategy in acute myeloid leukemia.
|
Clin Cancer Res
|
2013
|
1.30
|
|
18
|
Improved nonrelapse mortality and infection rate with lower dose of antithymocyte globulin in patients undergoing reduced-intensity conditioning allogeneic transplantation for hematologic malignancies.
|
Biol Blood Marrow Transplant
|
2009
|
1.29
|
|
19
|
Bortezomib added to daunorubicin and cytarabine during induction therapy and to intermediate-dose cytarabine for consolidation in patients with previously untreated acute myeloid leukemia age 60 to 75 years: CALGB (Alliance) study 10502.
|
J Clin Oncol
|
2012
|
1.23
|
|
20
|
Single-agent lenalidomide induces complete remission of acute myeloid leukemia in patients with isolated trisomy 13.
|
Blood
|
2008
|
1.16
|
|
21
|
Epigenetics in acute myeloid leukemia.
|
Semin Oncol
|
2008
|
1.16
|
|
22
|
Allogeneic stem cell transplantation for patients with relapsed chemorefractory aggressive non-hodgkin lymphomas.
|
Biol Blood Marrow Transplant
|
2009
|
1.13
|
|
23
|
Hyperglycemia in patients with acute myeloid leukemia is associated with increased hospital mortality.
|
Cancer
|
2007
|
1.11
|
|
24
|
A LC-MS/MS method for the analysis of intracellular nucleoside triphosphate levels.
|
Pharm Res
|
2009
|
1.07
|
|
25
|
Targeting AML1/ETO-histone deacetylase repressor complex: a novel mechanism for valproic acid-mediated gene expression and cellular differentiation in AML1/ETO-positive acute myeloid leukemia cells.
|
J Pharmacol Exp Ther
|
2007
|
1.06
|
|
26
|
Phase I study of GTI-2040, an antisense to ribonucleotide reductase, in combination with high-dose cytarabine in patients with acute myeloid leukemia.
|
Clin Cancer Res
|
2008
|
1.05
|
|
27
|
Lenalidomide-mediated enhanced translation of C/EBPα-p30 protein up-regulates expression of the antileukemic microRNA-181a in acute myeloid leukemia.
|
Blood
|
2012
|
1.04
|
|
28
|
A specific picomolar hybridization-based ELISA assay for the determination of phosphorothioate oligonucleotides in plasma and cellular matrices.
|
Pharm Res
|
2006
|
0.99
|
|
29
|
Low dose decitabine in very high risk relapsed or refractory acute myeloid leukaemia in children and young adults.
|
Br J Haematol
|
2013
|
0.97
|
|
30
|
A phase I biological study of MG98, an oligodeoxynucleotide antisense to DNA methyltransferase 1, in patients with high-risk myelodysplasia and acute myeloid leukemia.
|
Clin Cancer Res
|
2008
|
0.95
|
|
31
|
A Scalable, Flexible Workflow for MethylCap-Seq Data Analysis.
|
IEEE Int Workshop Genomic Signal Process Stat
|
2011
|
0.94
|
|
32
|
Acute lymphoblastic leukemia.
|
J Natl Compr Canc Netw
|
2012
|
0.93
|
|
33
|
Addition of infliximab to standard acute graft-versus-host disease prophylaxis following allogeneic peripheral blood cell transplantation.
|
Biol Blood Marrow Transplant
|
2008
|
0.91
|
|
34
|
Methods for high-throughput MethylCap-Seq data analysis.
|
BMC Genomics
|
2012
|
0.91
|
|
35
|
Eradicating acute myeloid leukemia in a Mll(PTD/wt):Flt3(ITD/wt) murine model: a path to novel therapeutic approaches for human disease.
|
Blood
|
2013
|
0.90
|
|
36
|
High-dose melphalan versus busulfan, cyclophosphamide, and etoposide as preparative regimens for autologous stem cell transplantation in patients with multiple myeloma.
|
Leuk Res
|
2006
|
0.88
|
|
37
|
Phase I study of azacitidine and bortezomib in adults with relapsed or refractory acute myeloid leukemia.
|
Leuk Lymphoma
|
2013
|
0.86
|
|
38
|
Long-term outcomes of allogeneic stem cell transplant recipients after calcineurin inhibitor-induced neurotoxicity.
|
Br J Haematol
|
2003
|
0.86
|
|
39
|
SPARC promotes leukemic cell growth and predicts acute myeloid leukemia outcome.
|
J Clin Invest
|
2014
|
0.86
|
|
40
|
Chimerism and clinical outcomes of 110 recipients of unrelated donor bone marrow transplants who underwent conditioning with low-dose, single-exposure total body irradiation and cyclophosphamide.
|
Blood
|
2004
|
0.85
|
|
41
|
inv(16)/t(16;16) acute myeloid leukemia with non-type A CBFB-MYH11 fusions associate with distinct clinical and genetic features and lack KIT mutations.
|
Blood
|
2012
|
0.84
|
|
42
|
Higher busulfan dose intensity does not improve outcomes of patients undergoing allogeneic haematopoietic cell transplantation following fludarabine, busulfan-based reduced toxicity conditioning.
|
Hematol Oncol
|
2011
|
0.83
|
|
43
|
In vivo quantification of active decitabine-triphosphate metabolite: a novel pharmacoanalytical endpoint for optimization of hypomethylating therapy in acute myeloid leukemia.
|
AAPS J
|
2012
|
0.80
|
|
44
|
Recent advances in allogeneic hematopoietic stem-cell transplantation.
|
J Lab Clin Med
|
2003
|
0.80
|
|
45
|
Pharmacokinetics and dose escalation of the heat shock protein inhibitor 17-allyamino-17-demethoxygeldanamycin in combination with bortezomib in relapsed or refractory acute myeloid leukemia.
|
Leuk Lymphoma
|
2013
|
0.80
|
|
46
|
MicroRNA-29b mediates altered innate immune development in acute leukemia.
|
J Clin Invest
|
2016
|
0.78
|
|
47
|
Effect of age on the pharmacokinetics of busulfan in patients undergoing hematopoietic cell transplantation; an alliance study (CALGB 10503, 19808, and 100103).
|
Cancer Chemother Pharmacol
|
2014
|
0.77
|
|
48
|
Quantification of valproic acid and its metabolite 2-propyl-4-pentenoic acid in human plasma using HPLC-MS/MS.
|
J Chromatogr B Analyt Technol Biomed Life Sci
|
2006
|
0.76
|
|
49
|
Phase I study of GTI-2040, a ribonucleotide reductase antisense, with high dose cytarabine in patients with relapsed/refractory acute myeloid leukemia.
|
Leuk Lymphoma
|
2013
|
0.76
|
|
50
|
Development and validation of a rapid and sensitive high-performance liquid chromatography-mass spectroscopy assay for determination of 17-(allylamino)-17-demethoxygeldanamycin and 17-(amino)-17-demethoxygeldanamycin in human plasma.
|
J Chromatogr B Analyt Technol Biomed Life Sci
|
2008
|
0.76
|
|
51
|
Post-remission therapy in acute myeloid leukemia: what should I do now?
|
Haematologica
|
2008
|
0.75
|
|
52
|
Evidence-based mini-review: Should patients over the age of 60 with INT-2 or high-risk myelodysplastic syndrome undergo allogeneic stem cell transplantation prior to progression to acute myelogenous leukemia?
|
Hematology Am Soc Hematol Educ Program
|
2010
|
0.75
|
|
53
|
Emerging immunotherapies in older adults with acute myeloid leukemia.
|
Curr Opin Hematol
|
2013
|
0.75
|
|
54
|
Acute Myeloid Leukemia, Version 3.2017, NCCN Clinical Practice Guidelines in Oncology.
|
J Natl Compr Canc Netw
|
2017
|
0.75
|
|
55
|
Making the most of hypomethylating agents in myelodysplastic syndrome.
|
Curr Opin Hematol
|
2017
|
0.75
|
|
56
|
Cancer immunology, success without sequencing.
|
J Natl Compr Canc Netw
|
2014
|
0.75
|